Similarly, obese patients with mild hypertriglyceridemia had significant improvements in lipid levels and liver fat mass and biomarkers of liver injury with LLF580 (an FGF21 analog) treatment every 4 weeks (122). The gene discussed is FGF21; the disease is hypertriglyceridemia.